SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

Recursion Pharmaceuticals Reports Wider Q1 Loss Amid Higher Costs, Revenue Rises

05/12/2021 05:31

09:20 AM EDT, 05/12/2021 (MT Newswires) -- Recursion Pharmaceuticals (RXRX) said Wednesday its Q1 net loss widened to $1.33 per diluted share from $0.85 a year ago after its operating costs increased to $33 million from $18.4 million.

Revenue totaled $2.6 million in the quarter ended March 31, up from $60,000 a year ago.

Cash and cash equivalents stood at $214.1 million as of the end of March versus $262.1 million as of Dec. 31, according to the drugmaker.

Analyst estimates weren't available.

Price: 22.70, Change: +0.04, Percent Change: +0.18